Regenxbio Inc (RGNX)
33.37
+0.25 (+0.75%)
USD |
NASDAQ |
Aug 12, 16:00
33.40
+0.02 (+0.07%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.443B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 6.24% |
| Valuation | |
| PE Ratio | 17.29 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.055 |
| Price to Book Value | 2.288 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 76.45% |
News
Headline
Wire
Time (ET)
SA Breaking News
08/13 16:00
PR Newswire
08/10 07:05
MT Newswires
08/04 14:53
MT Newswires
08/04 08:28
PR Newswire
08/03 16:05
MT Newswires
08/03 11:32
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/02/2022* | -- | Results | Q3 2022 | -- | -1.47 | -- | |
| 11/02/2022* | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -1.58 | -1.58 | -0.21% | |
| 08/03/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | -1.79 | -1.29 | -39.30% | |
| 05/04/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/01/2022 | -- | Results | Q4 2021 | 6.67 | 4.31 | 54.76% | |
| 03/01/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
| URL | https://www.regenxbio.com |
| Investor Relations URL | http://ir.regenxbio.com/ |
| HQ State/Province | Maryland |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 02, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 12, 2022.
Fundamentals
| Revenue (TTM) | 484.30M |
| Total Expenses (TTM) | 362.11M |
| Net Income (TTM) | 90.72M |
| Total Assets (Quarterly) | 953.44M |
| Total Liabilities (Quarterly) | 322.92M |
| Shareholders Equity (Quarterly) | 630.52M |
| Cash from Operations (TTM) | 181.33M |
| Cash from Investing (TTM) | -291.93M |
| Cash from Financing (TTM) | -24.40M |
Ratings
Profile
Edit
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
| URL | https://www.regenxbio.com |
| Investor Relations URL | http://ir.regenxbio.com/ |
| HQ State/Province | Maryland |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 02, 2022 (est.) |
| Last Earnings Release | Aug. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| F000016ZD9 | 559.00 USD | 5.59% |
| SMHCLX | 461.00 USD | 4.61% |
| PBE | 10.37M USD | 3.98% |
| F00001DUH5 | 393.00 USD | 3.93% |
| GNOM | 5.467M USD | 2.15% |
| EWSC | 137614.0 USD | 0.25% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| RGNX Tweets |